Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2010
10/07/2010US20100255104 Pharmaceutical formulation of taxane
10/07/2010US20100255103 Mesoporous Silica Nanoparticles for Biomedical Applications
10/07/2010US20100255102 Sterilization of dispersions of nanoparticulate active agents with gamma radiation
10/07/2010US20100255080 Liposomal ALA pharmaceutical and cosmeceutical compositions and methods of treatment
10/07/2010US20100255074 Transmembrane prostatic acid phosphatase
10/07/2010US20100255066 Orally-administered agent
10/07/2010US20100255063 Compressed Chewing Gum Tablet
10/07/2010US20100255057 Device for actively removing a target cell from blood or lymph of a vertebrate subject
10/07/2010US20100255056 Fibronectin Type III Domain Based Scaffold Compositions, Methods And Uses
10/07/2010US20100255040 Composition for improving tlr-mediated cellular immunity comprising poly-gamma-glutamic acid
10/07/2010US20100255027 Papilloma pseudovirus and preparation
10/07/2010US20100255023 Dendritic cell vaccine compositions and uses of same
10/07/2010US20100255020 Method for inducing cytotoxic t-cells, cytotoxic t-cell inducers, and pharmaceutical compositions and vaccines employing them
10/07/2010US20100255019 Ii-KEY/HER-2/NEU HYBRID CANCER VACCINE
10/07/2010US20100255017 Purified hemocyanin obtained from fissurella latimarginata, fissurella cumingi or fissurella maxima; subunit of purified hemocyanin; use of hemocyanin, its subunit or immunogenic fragments and compositions containing the same
10/07/2010US20100255013 Glycoprotein compositions
10/07/2010US20100255012 Recombinant fucose modified monovalent half-antibodies obtained by molecular engineering
10/07/2010US20100255011 Compositions and methods for modulating the activity of complement regulatory proteins on target cells
10/07/2010US20100255010 Anti-her antibodies
10/07/2010US20100255008 Antibodies against human tweak and uses thereof
10/07/2010US20100255007 Therapeutic agents for graft-versus-host disease comprising interleukin 6 receptor inhibitor as active ingredient
10/07/2010US20100255006 Novel molecules of the pyrin/nbs/lrr protein family and uses thereof
10/07/2010US20100255004 Receptor tyrosine kinase profiling
10/07/2010US20100255003 Immune Disease Medicament Comprising a Modulator of the Binding Between a Heparin Bindin Domain of Thrombospondin-1 and a Beta1 Integrin
10/07/2010US20100254999 Eg-vegf nucleic acids and polypeptides and methods of use
10/07/2010US20100254996 Synergistic treatment of cells that express epha2 and erbb2
10/07/2010US20100254995 Polypeptides, antibody variable domains and antagonists
10/07/2010US20100254989 Bispecific Anti ErbB1 / Anti c Met Antibodies
10/07/2010US20100254988 Bispecific Anti ErbB2 / Anti cMet Antibodies
10/07/2010US20100254987 Engineered proteins with high affinity for dota chelates
10/07/2010US20100254985 Protein Formulations
10/07/2010US20100254982 Cancer specific antibody and cell surface proteins
10/07/2010US20100254980 Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6)
10/07/2010US20100254979 Humanized PAI-1 Antibodies and Uses Thereof
10/07/2010US20100254977 Engineered anti-alpha v-integrin hybrid antibodies
10/07/2010US20100254976 Use of protease nexin 1 inhibitors to reduce metastasis
10/07/2010US20100254964 Modified Bouganin Proteins, Cytotoxins and Methods and Uses Thereof
10/07/2010US20100254963 Peg-modified arginine/lysine oxidoreductase
10/07/2010US20100254949 Prebiotic oligosaccharides
10/07/2010US20100254940 Compositions and Methods for Regulating an Immune Response in a Subject
10/07/2010US20100254919 Topical Turmeric Skin Care Products
10/07/2010US20100254914 Nanoworms for in vivo tumor targeting
10/07/2010US20100254909 Thermolabile liposome with a controlled release temperature
10/07/2010US20100254906 New compositions based on polysaccharides grafted by polyamine or polysulphurised compounds
10/07/2010US20100254901 Compositions comprising nucleic acid aptamers
10/07/2010US20100254898 ANTIBODIES THAT BIND GalNAc1-3Gal, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME
10/07/2010US20100254896 Methods and compositions related to adenoassociated virus-phage particles
10/07/2010CA2794577A1 Semaphorin 3c (sema3c) inhibitor therapeutics, methods, and uses
10/07/2010CA2757615A1 Plasminogen activator inhibitor-1 inhibitor
10/07/2010CA2757485A1 Pyrimidine substituted purine compounds as kinase (s) inhibitors
10/07/2010CA2757463A1 Lyophilization cakes of proteasome inhibitors
10/07/2010CA2757415A1 Autotaxin inhibitors
10/07/2010CA2757413A1 Heterocyclic compounds as autotaxin inhibitors
10/07/2010CA2757210A1 C6orf167 peptides and vaccines containing the same
10/07/2010CA2757208A1 Method for manufacturing 1,5-benzodiazepine derivative
10/07/2010CA2757188A1 Pyrimidine compound
10/07/2010CA2756988A1 Anti-fcrh5 antibodies and immunoconjugates and methods of use
10/07/2010CA2756871A1 Substituted heterocyclic compounds
10/07/2010CA2756870A1 Substituted indolo-pyridinone compounds
10/07/2010CA2756810A1 Pyrazolo-pyrrolopyridine-dione derivatives useful in the treatment of cancer
10/07/2010CA2756809A1 Substituted tetrahydropyrazolo-pyrido-azepin compounds
10/07/2010CA2756808A1 Substituted indolo-piperidine compounds
10/07/2010CA2756807A1 Substituted dipyrido-pyrimido-diazepine and benzo-pyrido-pyrimido compounds
10/07/2010CA2754646A1 Treatment of cancer with a humanized anti-egfr igg1 antibody and irinotecan
10/07/2010CA2749512A1 Antigenic determinants recognized by anti-human death receptor dr5 monoclonal antibody ad5-10, derivatives and use thereof
10/07/2010CA2738573A1 Compositions of propane-1 sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and uses thereof
10/07/2010CA2699140A1 Nanoparticles for cancer sonodynamic and photodynamic therapy
10/06/2010EP2237042A1 Marker for determination of sensitivity to anti-cancer agent
10/06/2010EP2236605A1 Human anti- 9 integrin antibody
10/06/2010EP2236521A1 Y-type polyethylene glycol modified g-csf and preparation method and use thereof
10/06/2010EP2236503A1 Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
10/06/2010EP2236172A1 Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
10/06/2010EP2236152A1 Albumin fusion proteins
10/06/2010EP2236150A1 Method for increasing the therapeutic efficacy of curcuminoids and analogues
10/06/2010EP2236146A1 Composition for reducing oxidative stress and/or side effects occurring during cancer chemotherapy or improving nutritional status during cancer chemotherapy
10/06/2010EP2236145A1 Pharmaceutical composition and combined agent
10/06/2010EP2236139A1 Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
10/06/2010EP2236134A1 Combinations of DMXAA and other anti-cancer agents
10/06/2010EP2236131A2 Compositions for manipulating the lifespan and stress response of cells and organisms
10/06/2010EP2235189A1 Methods for inhibiting angiogenesis using egfl8 antagonists
10/06/2010EP2235178A2 Compositions and methods for modulating vascular endothelial growth factor c (vegf-c) expression
10/06/2010EP2235175A1 Polypeptide-nucleic acid conjugates and uses thereof
10/06/2010EP2235063A1 Anti-hedgehog antibodies
10/06/2010EP2235044A1 New polypeptides having affinity for her2
10/06/2010EP2235036A1 Saccharide lupane derivatives, their use and pharmaceutical compositions containing these derivatives
10/06/2010EP2235018A1 Pharmaceutically acceptable salts of methyl (3-{ ýý3-(6- amino- 2-butoxy-8-oxo-7, 8-dihydro-9h-purin-9-yl) propyl¨(3- morpholin-4-ylpropyl) amino¨methyl }phenyl) acetate and their use in therapy
10/06/2010EP2235017A1 Spiroindolinone derivatives as anticancer agents
10/06/2010EP2235010A1 Bicyclic derivatives for use in the treatment of androgen receptor associated conditions
10/06/2010EP2235004A1 Indazolyl, benzimidazolyl, benzotriazolyl substituted indolmone derivatives as kinase inhibitors useful in the treatment of cancer
10/06/2010EP2235002A1 4-pyridinone compounds and their use for cancer
10/06/2010EP2235001A1 4-pyridinone compounds and their use for cancer
10/06/2010EP2234982A1 Substituted hydantoins as mek kinase inhibitors
10/06/2010EP2234966A2 Azetidine derivatives, their preparation and their application in therapy
10/06/2010EP2234641A2 Monoclonal antibodies against cd32b
10/06/2010EP2234610A2 Use of aminopeptidase inhibitors or azaindole compounds for preventing or treating cancerous metastases from epithelial origin
10/06/2010EP1996590B1 Spiroindolinone derivatives
10/06/2010EP1874760B1 (lh-ind0l-7-yl)-( (pyrimidin-2 -yl-amino) methanone derivatives and related compounds as igf-rl inhibitors for treating cancer
10/06/2010EP1871415B1 Composition for treating cancer adapted for intra-tumoral asministration and uses thereof
10/06/2010EP1736484B1 An gene engineering recombinant anti-cea, anti-cd3 and anti-cd28 single-chain tri-specific antibody
10/06/2010EP1594958B1 Activation and expansion of t cells
1 ... 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 ... 2211